UNSPSC 51373300: Combination opioid analgesics

This classification denotes combination drugs and preparations that constitute pain-relieving agents or analgesics do bind to opioid receptors, which do derive from opium or morphine or which scientists synthesize therefrom, which are addictive, which are narcotics, and which therefore bear the term OPIOID ANALGESICS. Typical constituents combination opioid analgesic constituents are buprenorphine, droperidol, hydrocodone, meperidine, morphine, etc.

UNSPSC 51373300 Combination opioid analgesics is a Class code that in recent state and local procurement practice encompasses not only opioid products themselves but also broader pharmaceutical supply and harm-reduction initiatives, including naloxone acquisition and direct-to-manufacturer pharmacy programs. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances managing pharmaceutical inventories for public health and employee benefit programs. The work being solicited ranges from standalone naloxone and drug-deactivation system procurement for community health initiatives to large-scale generic pharmaceutical contracting through authorized wholesaler networks and exploratory efforts to establish direct manufacturer-to-state relationships for prescription fulfillment outside traditional pharmacy benefit manager channels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2026 (note: the due date shown in the source appears inconsistent with the posted date; the most recent guidance references July 26, 2023). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to build direct contracting relationships with pharmaceutical suppliers outside traditional PBM and GPO structures. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to work through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance standards, with a contract term of two years starting July 1, 2026.